Propanc Biopharma is a biopharmaceutical company developing a novel approach to prevent recurrence and metastasis from solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. Our novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
Company profile
Ticker
PPCB
Exchange
Website
CEO
James Nathanielsz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Propanc Health Group Corp
SEC CIK
Corporate docs
Subsidiaries
Propanc Pty Ltd • Propanc (UK) Ltd ...
IRS number
300662986
PPCB stock data
Latest filings (excl ownership)
10-Q
2023 Q1
Quarterly report
14 Nov 22
8-K
Departure of Directors or Certain Officers
1 Nov 22
8-K
Entry into a Material Definitive Agreement
12 Oct 22
DEF 14C
Information statement
5 Oct 22
10-K
2022 FY
Annual report
28 Sep 22
8-K
Entry into a Material Definitive Agreement
27 Sep 22
PRE 14C
Preliminary information
23 Sep 22
8-K
Entry into a Material Definitive Agreement
18 Aug 22
8-K
Amendments to Articles of Incorporation or Bylaws
11 Jul 22
8-K
Entry into a Material Definitive Agreement
7 Jul 22
Latest ownership filings
SC 13G
Sylva International LLC
8 Sep 21
4
Julian Norman Kenyon
20 Aug 21
4
James Andrew Nathanielsz
20 Aug 21
3
JOSEF ZELINGER
20 Aug 21
SC 13G
Oasis Capital, LLC
7 Jul 20
SC 13G
L2 Capital, LLC
7 Jul 20
3
Carlo M Campiciano
28 Jun 19
4
Julian Norman Kenyon
22 May 19
4
James Andrew Nathanielsz
17 May 19
SC 13G
Propanc Biopharma, Inc.
14 Sep 18
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jun 22 | Jun 21 | Jun 20 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 19.40 k | 19.40 k | 19.40 k | 19.40 k | 19.40 k | 19.40 k |
| Cash burn (monthly) | (no burn) | 2.20 k | 205.77 k | 202.29 k | 169.77 k | 121.57 k |
| Cash used (since last report) | n/a | 9.20 k | 859.48 k | 844.95 k | 709.14 k | 507.81 k |
| Cash remaining | n/a | 10.20 k | -840.09 k | -825.56 k | -689.74 k | -488.41 k |
| Runway (months of cash) | n/a | 4.6 | -4.1 | -4.1 | -4.1 | -4.0 |
Institutional ownership, Q1 2021
0.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1 |
| Opened positions | 1 |
| Closed positions | 1 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 5.00 k |
| Total shares | 20.01 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| LVM Capital Management | 20.01 k | $5.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Aug 21 | Julian Norman Kenyon | Common stock, par value $0.001 | Grant | Acquire A | No | No | 0 | 3,420,000 | 0.00 | 3,420,005 |
| 17 Aug 21 | James Andrew Nathanielsz | Common stock, par value $0.001 | Grant | Acquire A | Yes | No | 0 | 2,800,000 | 0.00 | 2,800,000 |
| 17 Aug 21 | James Andrew Nathanielsz | Common stock, par value $0.001 | Grant | Acquire A | Yes | No | 0 | 5,928,000 | 0.00 | 5,928,004 |